

REMARKS

Prior to this amendment claims 1-20 and 32-35 were withdrawn from consideration as relating to non-elected inventions. Claims 26, 28 and 29 were withdrawn by the Examiner as not readable on the elected species. Claims 21-25, 27, 30 and 31 were pending. No changes to the pending claims are introduced by this amendment.

Rejection under 35 U.S.C. §103(a) over Hutchinson et al.

Claims 21-23 and 30 were rejected by the Examiner in the Office Action of December 18, 2002 as allegedly obvious under 35 U.S.C. §103(a) over the teachings of Hutchinson et al. *Rev. in Immunogenetics*, volume 1, issue 3: 323-333, 1999 (Hereinafter 'Hutchinson').

Applicants' attorney contacted Blackwell Munksgaard, the publisher of the journal "*Reviews in Immunogenetics*" to ascertain the date that Hutchinson became publicly available. Katrine Flindt Christensen, the Web Service Project Manager at Blackwell Munksgaard, Copenhagen, Denmark responded that the official publication date for *Reviews in Immunogenetics*, volume 1, issue 3 was November 08, 1999. The cover discloses the month of publication as September, but, according to Ms. Christensen, the issue was delayed. A copy of an e-mail message from Ms. Christensen detailing these facts is attached as Exhibit 1.

The Present Invention Antedates Hutchinson

As presently claimed, the invention relates to a composition comprising a pharmaceutically effective amount of a TGF- β antagonist and an immunosuppressive agent. The

invention was conceived and reduced to practice prior to the November 08, 1999 publication date of Hutchinson, as demonstrated by the rule 131 declaration attached as Exhibit 2. In this declaration, co-inventor Dr. Mannikam Suthanthiran states that he is the senior co-author of an article by Hojo et al. in *Nature*, volume 397, pages 530-534 (February 11, 1999). Applicants note that the Hojo et al. article was cited by the Applicant in an Information Disclosure Statement filed November 13, 2001. A copy of the Hojo et al. article is attached.

The conception of the invention of a composition comprising a pharmaceutically effective amount of a TGF- β antagonist and an immunosuppressive agent is evident from the statement by Hojo et al. at page 533, in the first column, last paragraph:

We investigated the effect of anti-TGF- β antibodies (1D11.16 IgG₁) on the cyclosporine-induced increase in the metastases to determine whether *in vivo* tumour progression by cyclosporine was dependent on TGF- β ₁. Anti- TGF- β antibodies, but not control antibodies, prevented the cyclosporine-induced increase in metastases. (Citation omitted).

A reduction of the claimed invention to practice is apparent from the Hojo et al. article in the experiment described at page 533, bridging the first and second columns. The experiment demonstrates the induction of metastases by cyclosporine as well as a reduction in the number of metastases by an anti-TGF- β antibody after induction by cyclosporine in SCID-beige mice (that have little or no immune system function). In relevant part, this paragraph states:

The number of pulmonary metastases was 350 ± 22 (mean \pm s.e.m., $n=12$) in control mice, 441 ± 20 ($n=10$) in cyclosporine-treated mice, 284 ± 34 ($n=8$) in mice treated with cyclosporine and anti-TGF- β , and 490 ± 56 ($n=4$) in mice treated with cyclosporine and control IgG₁ ($P=0.0005$; one-way ANOVA). The reduction in the number of metastases found following the administration of anti-TGF- β antibodies to cyclosporine-treated mice was significant at $P<0.01$ by ANOVA (Bonferoni P-value). In contrast, there was no significant difference between the number of metastases found in mice treated with combined cyclosporine and control IgG₁ ($P>0.05$).

Therefore the conception and reduction of the presently claimed invention was disclosed in the article of Hojo et al.

Also enclosed herewith is a declaration of Dr. Suthanthiran under Rule 132 in accord with *In re Katz*. In this declaration, Dr. Suthanthiran explains that he and Dr. Hojo are co-inventors named in the present application. Moreover, the declaration establishes that the other co-authors of the Hojo et al. publication, Drs. Takashi Morimoto, Mary Maluccio, Tomohiko Asano, Kengo Morimoto, Milagros Lagman, Toshikazu Shimbo, did not contribute to the conception of the present invention.

Thus, the Hojo et al article was a publication of the present invention by the inventors. Applicants have thereby established that the claimed invention was made prior to the February 11, 1999 publication date of Hojo et al. Accordingly, Hutchinson, which, as established above, was published on November 8, 1999, is not available as a reference against the present invention.

Moreover, it should be noted that the present application claims the benefit of U.S. Provisional Application No. 60/181,526 filed February 10, 2000. Accordingly, the Hojo et al. article was published less than one year earlier than the priority date of the present application. Therefore, the Hojo et al. article does not constitute a bar under §102(b) against the present application.

Hutchinson did not render the claimed invention obvious

Furthermore, even if Hutchinson constituted prior art against the present application, and Applicants emphasize that they have already established that it does not, Hutchinson does not render the claimed invention obvious. Hutchinson merely discloses that there is a higher incidence of certain genetic markers, including high TGF- β 1 expression, associated with chronic rejection in lung transplant recipients (page 328, right col. and Fig.5). There is no indication in Hutchinson that this high TGF- β 1 expression is a contributing cause, or an effect of the chronic rejection observed. One of ordinary skill would have had no way of distinguishing between these possibilities from the disclosure of Hutchinson. For this reason, one of skill would not have been able to predict whether administration of an anti-TGF- β 1 antibody would have had any effect on the chronic rejection in these transplant patients.

At most, Hutchinson may have rendered the present invention obvious to try. Even if such a conclusion were correct, which Applicants doubt, it is well established that “obvious to try” is an insufficient standard to establish obviousness under §103.

Therefore, the use of anti-TGF- β 1 antibody to ameliorate chronic rejection was not obvious from the disclosure of Hutchinson, much less a composition of the present invention, which comprises a pharmaceutically effective amount of a TGF- β antagonist and an immunosuppressive agent.

For the above recited reasons, the rejection of claims 21-23 and 30 as allegedly obvious under 35 U.S.C. §103(a) over the teachings of Hutchinson must be withdrawn.

Rejection under 35 U.S.C. §103(a) over Ader & Rostaing in view of Hutchinson

At paragraph 5 of Office Action of December 18, 2002, the Examiner rejected claims 21-23 and 31 as allegedly being obvious under 35 U.S.C. §103(a) over the teachings of Ader and Rostaing *Curr. Opin. Nephrol. Hypertens.*, 7: 539-545, 1998 (hereinafter 'Ader') in view of Hutchinson (supra). The Examiner cited Ader for the teaching that FK506 causes nephrotoxicity in transplant patients. Further, the Examiner cited Hutchinson as allegedly teaching that nephrotoxicity is probably caused by TGF- β 1. According to the Examiner, the invention of claims 21-23 and 31 would have been obvious to one of ordinary skill over the teachings of Ader in view of the disclosure of Hutchinson.

As explained above, the Hutchinson is not available as art against the present invention. Further, the teaching of Ader alone, which relates to the nephrotoxicity of FK506, does not disclose or suggest the presently claimed composition comprising a pharmaceutically effective amount of a TGF- β antagonist and an immunosuppressive agent.

Therefore, Applicants respectfully requests that the rejection of claims 21-23 and 31 under 35 U.S.C. §103(a) over the teachings of Ader in view of the disclosure of Hutchinson be withdrawn.

Rejection under 35 U.S.C. §103(a) over Novak in view of Ohmori et al.

At paragraph 6 of the Office Action the Examiner rejected claims 21-25, 27 and 30 as allegedly obvious under 35 U.S.C. §103(a) over Novak, *Nature Medicine*, 5(4): 382, April 1999, in view of Ohmori et al. *Curr. Opin. Nephrol. Hypertens.*, 7: 539-545, 1998 (hereinafter 'Ohmori').


According to the Examiner, Novak teaches that transplant patients receiving immunosuppression are more susceptible to cancer and that cyclosporine promotes tumor progression directly, and further, that the mechanism is mediated by TGF- β . The Examiner then cited Ohmori for disclosure of the use of anti-TGF antibodies in the treatment of cancer. Therefore, according to the Examiner, the invention of claims 21-25, 27 and 30 would have been obvious to one of ordinary skill in view of the cited references.

In fact, the Novak article is a commentary in the News and Views section of *Nature Medicine* on the earlier publication of Hojo et al. in *Nature*. As described above, the Hojo et al. article contains a disclosure of the present invention by the present inventors and their collaborators. Accordingly, the Novak article does not constitute prior art against the present application.

Further, the disclosure in Ohmori of the use of anti-TGF antibodies in the treatment of cancer alone clearly fails to render obvious a composition comprising a pharmaceutically effective amount of a TGF- β antagonist and an immunosuppressive agent, as presently claimed. Therefore, Applicants respectfully request that the rejection of claims 21-25, 27 and 30 under 35 U.S.C. §103(a) over Novak in view of Ohmori be withdrawn.

For all the above-explained reasons, reconsideration of the rejections of December 18, 2002 is respectfully requested. If any further issues remain to be addressed, the Examiner is respectfully invited to contact Applicants' attorney at the telephone number shown below.

Respectfully submitted,


Algis Anilionis, Ph.D.
Attorney for Applicant(s)
Registration No. 36,995

Hoffmann & Baron, LLP
6900 Jericho Turnpike
Syosset, NY 11791
(516) 822-3550
169950_1

Anilionis, Algis

From: Christensen Katrine Flindt [K.Christensen@mks.blackwellpublishing.com]
Sent: Monday, February 10, 2003 9:23 AM
To: Anilionis, Algis
Subject: RE: Request for information

Dear Dr. Anilionis,

The official publication date for Reviews in Immunogenetics vol. 1 issue 3 is 08 November 1999. The cover month say September but the issue was delayed.

Ad 2 – 4 days for the editors to have an advance copy and 10 – 20 days before the print issue was in the subscriber's mailbox.

This issue is not online.

I hope this is a fulfilling answer to your question

Yours sincerely
Katrine Flindt Christensen

Katrine Flindt Christensen,
Web Service Project Manager
Blackwell Munksgaard
1 Rosenørns Allé, P.O.Box 227, DK-1502 Copenhagen V, Denmark

Ph: +45 77 33 33 33 fax: +45 77 33 33 77
e-mail: kfc@munksgaard.dk

-----Original Message-----

From: Anilionis, Algis [mailto:AAnilionis@hoffmannbaron.com]
Sent: 6. februar 2003 16:09
To: Christensen Katrine Flindt
Subject: Request for information

Please could you let me know the actual publication date (i.e. date of first distribution or web publication including the month - and day if possible) of Reviews in Immunogenetics vol. 1 (issue 3). We are interested in the article at pages 323-333 by Hutchinson et al.

For patent purposes we need to know when this article was first publicly available.
Thank you for your help in this matter.

Very truly,
Algis Anilionis, Ph.D.
Hoffmann & Baron, LLP
6900 Jericho Turnpike
Syosset, New York, NY 11791
Tel. (516) 822-3550
Fax (516) 822-3582
Return e-mail address: aanilionis@hbiplaw.com

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Suthanthiran, M.	Examiner:	Anne Holleran
Serial No:	09/780,953	Group Art Unit:	1642
Filed:	February 9, 2001	Docket:	955-3P/CON
For:	USE OF TGF- β ANTAGONISTS TO INHIBIT TUMOR CELL FORMATION OR PROGRESSION	Dated:	March 13, 2003

Assistant Commissioner for Patents
Washington, DC 20231

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
Assistant Commissioner for Patents, Washington, D.C.*

20231 on March 13, 2003

Dated: 3/13/03

DECLARATION OF MANIKKAM SUTHANTHIRAN M.D.**UNDER 37 C.F.R §1.132 IN ACCORD WITH *In re Katz***

Sir:

I, Manikkam Suthanthiran, M.D., holding the position of Transplantation Physician in Chief at the Department of Transplantation Medicine and Extracorporeal Therapy, and Chief of the Division of Nephrology, and Departments of Medicine and Surgery, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA, declare as follows:

- I. I am a co-inventor of the above-captioned patent application.

Declaration of Manikkam Suthanthiran, M.D.

Application No. 09/780,953
Filing Date: February 9, 2001
Docket: 955-3P/CON

2. I am the senior author of a research paper titled, "Cyclosporine induces cancer progression by a cell-autonomous mechanism" published in Nature, in the February 11, 1999 issue, in volume 397, pages 530-534. This paper names Minoru Hojo, Takashi Morimoto, Mary Meluccio, Tomohiko Asano, Kengo Morimoto, Milagros Lagman, Toshikazu Shimbo and myself as co-authors.
3. Minoru Hojo, was a researcher in the Division of Nephrology, Department of Medicine, Weill Medical College of Cornell University, New York. Dr. Hojo is a co-inventor of the present invention.
4. Takashi Morimoto was a researcher in the Department of Cell Biology, New York University School of Medicine who did not contribute to the conception of the present invention.
5. Mary Maluccio was house staff in Department of Surgery, Weill Medical College of Cornell University, New York who did not contribute to the conception of the present invention.
6. Tomohiko Asano is a physician at the Department of Urology, National Defense Medical College, 3-2-Namiki, Tokorozawa, Suituma 359, Japan. Dr. Asano did not contribute to the conception of the present invention.

Declaration of Manikkam Suthanthiran, M.D.

Application No. 09/780,953
Filing Date: February 9, 2001
Docket: 955-3P/CON

7. Kengo Morimoto is a physician at the Department of Pediatrics, Mizonokuchi Hospital, Teikyo University School of Medicine, 3-8-3 Mizonokuchi, Takatsu ku, Kawasaki 213, Japan. Dr. Morimoto did not contribute to the conception of the present invention.
8. Milagros Lagman is a laboratory supervisor at the Department of Transplantation Medicine and Extracorporeal Therapy, Division of Nephrology, and Department of Medicine, Weill Medical College of Cornell University, New York. Ms. Lagman did not contribute to the conception of the present invention. Ms. Lagman contributed her expertise under my direction and supervision in maintaining tumor cell lines, ordering mice and the reagents required.
9. Toshikazu Shimbo is at the Department of Pediatrics, Mizonokuchi Hospital, Teikyo University School of Medicine, 3-8-3 Mizonokuchi, Takatsu ku, Kawasaki 213, Japan. Dr. Shimbo did not contribute to the conception of the present invention.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States Code, and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Dated: 3/14/03

169668_1

Respectfully submitted,


M. Suthanthiran, M.D.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Suthanthiran, M.	Examiner:	Anne Holleran
Serial No:	09/780,953	Group Art Unit:	1642
Filed:	February 9, 2001	Docket:	955-3P/CON
For:	USE OF TGF- β ANTAGONISTS TO INHIBIT TUMOR CELL FORMATION OR PROGRESSION	Dated:	March 14, 2003

Assistant Commissioner for Patents
Washington, DC 20231

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
Assistant Commissioner for Patents, Washington, D.C.*

20231 on March 14, 2003

Dated: 3/14/03

DECLARATION OF MANIKKAM SUTHANTHIRAN M.D.**UNDER 37 C.F.R §1.131**

Sir:

I, Manikkam Suthanthiran, M.D., holding the position of Transplantation Physician In Chief in the Department of Transplantation Medicine and Extracorporeal Therapy, and Chief of the Division of Nephrology, and Departments of Medicine and Surgery, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA, declare as follows:

1. I am a co-inventor of the above-captioned patent application.
2. The claimed invention in the above-captioned application is described in the research paper entitled, "Cyclosporine induces cancer progression by a cell-autonomous

Declaration of Manikkam Suthanthiran, M.D.

Application No. 09/780,953
Filing Date: February 9, 2001
Docket: 955-3P/CON

mechanism" Hojo et al., published in *Nature*, in the February 11, 1999 issue, volume 397, pages 530-534.

3. I am the senior co-author of the above-referenced publication of Hojo et al. from which the conception of the present invention of a composition comprising a pharmaceutically effective amount of a TGF- β antagonist and an immunosuppressive agent is evident from the statement at page 533, in the first column, last paragraph:

We investigated the effect of anti-TGF- β antibodies (1D11.16 IgG₁) on the cyclosporine-induced increase in the metastases to determine whether *in vivo* tumour progression by cyclosporine was dependent on TGF- β ₁. Anti-TGF- β antibodies, but not control antibodies, prevented the cyclosporine-induced increase in metastases. (Citation omitted).

3. A reduction of the claimed invention to practice is apparent from the Hojo et al. article in the experiment described at page 533, bridging the first and second columns. The experiment demonstrates the induction of metastases by cyclosporine as well as a reduction in the number of metastases by an anti-TGF- β antibody after induction by cyclosporine in SCID-beige mice (that have little or no immune system function). In relevant part, this paragraph states:

The number of pulmonary metastases was 350 ± 22 (mean \pm s.e.m., $n=12$) in control mice, 441 ± 20 ($n=10$) in cyclosporine-treated mice, 284 ± 34 ($n=8$) in mice treated with cyclosporine and anti-TGF- β , and 490 ± 56 ($n=4$) in mice treated with cyclosporine and control IgG₁ ($P=0.0005$; one-way ANOVA). The reduction in

Declaration of Manikkam Suthanthiran, M.D.

Application No. 09/780,953
Filing Date: February 9, 2001
Docket: 955-3P/CON

the number of metastases found following the administration of anti-TGF- β antibodies to cyclosporine-treated mice was significant at $P < 0.01$ by ANOVA (Bonferoni P-value). In contrast, there was no significant difference between the number of metastases found in mice treated with combined cyclosporine and control IgG₁ ($P > 0.05$).

4. The co-filed Declaration of Dr. Suthanthiran under 37 C.F.R. 1.132 in accord with *In re Katz* establishes that the above-referenced publication of Hojo et al. is a publication of the present inventors and others, and was derived from the presently claimed invention.
5. Thus, the claimed subject matter of the above-captioned application was conceived and reduced to practice by me and my co-inventor, Dr. Hojo prior to February 11, 1999.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States Code, and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

Dated: 3/14/03



M. Suthanthiran, M.D.

locus. In agreement, the wing phenotypes (thickened veins and wing-edge loss) of N^{md-3} mutants are completely suppressed by $pk-sple^{13}$ (data not shown). The inhibitory effect of Sple provides a second mechanism for polarizing Notch signalling in R3/R4 that could be coordinated by Fz/Dsh (Fig. 4d).

In conclusion, Notch signalling is activated in R3/R4 in response to Fz/Dsh and we propose that Fz/Dsh sets up an initial bias in Notch activity between R3 and R4 by promoting D1 activity and inhibiting Notch via Sple in a coordinated manner. Feedback in the Notch pathway amplifies this bias so that even a subtle variation in the amount of signal received by Fz in the equatorial (pre-R3) and polar (pre-R4) cells in each ommatidium would generate distinct cell fates. This explains how a signal from the equator could be interpreted by the whole field of ommatidia (Fig. 4e) and is likely to be of widespread significance in the development of polarized structures within planar epithelia. The asymmetrical expression of Notch-pathway genes detected in feather primordia is consistent with this model²⁴. Furthermore, this mechanism for the coordinated regulation of Notch signalling can also explain how neural precursors develop at specific positions within competent proneural fields. □

Methods

Fly strains. Alleles used were: N^{ts1} , N^{md-3} , dsh^1 , fz^{R54} , Df^1 , Df^{68} , $sple^1$ and $pk-sple^{13}$. For analysis of $E(spl)$ a combination between $Df(3R)NF1^{P1}$ (removing $NF1$, $E(spl)md$ and $E(spl)my$ promoter²⁵; M.T.D.C. and S.J.B., unpublished data) and $Df(3R)E(spl)^{rob32.2}$ (removing all $E(spl)$ genes and $NF1$) was used. Rescue of $NF1$ activity²⁵ did not modify the eye phenotypes and no defects were observed in $NF1^{P2}/Df(3R)NF1^{P1}$, which eliminates $NF1$ only²⁵. For mis-expression studies we used heat-shock-inducible, intracellular Notch ($hs-N^{icd}$; ref. 15), a transmembrane-activated Notch derivative driven by *sevenless* enhancer (sev^E-N^{icd} ; ref. 17), and the Gal4/UAS-targeted expression system²⁶. UAS lines were: $UAS-N^{icd}$ (gift of M. Haenlin), $UAS-N^{dn}$ (ECN, containing Notch extracellular and transmembrane domains¹⁶), $UAS-dsh^1$, $UAS-E(spl)md$ and $UAS-E(spl)mb$. These were combined with *sev-Gal4* (expressed in R3, R4, R7, mystery and cone cells) and/or *spalt-Gal4* (expressed in R3, R4 and cone cells).

For N^{ts1} experiments, larvae were incubated at 30 °C for 6 h, returned to 25 °C for 10 h or until eclosion. N^{icd} expression was induced in $hs-N^{icd}$ larvae by 2 h at 37 °C. **mb0.5 transgenic lines.** A 487-bp fragment from the 1.9-kb genomic *HindIII* fragment upstream of $E(spl)md$ was amplified using the primers GATCTA-GATGCCATCAGATGTCAGC and CTACTAGTCTTTTGGCGCACAGTCAC, digested with *SpeI* (filled in) and *XbaI*, and ligated into *Asp718* (filled in) and *XbaI* sites of HZ50PL. Transgenic lines were established by injection in *cn;ry* flies using standard procedures and all lines gave identical patterns of expression.

Immunofluorescence. the following antibodies were used: rabbit anti- β -galactosidase (Cappel), rabbit anti-Bar²⁷, guinea-pig anti-Coracle²⁸, rat anti-Elav (Developmental Studies Hybridoma Bank), rat anti-Spalt (a gift of R. Barrio) and mouse monoclonal antibodies against β -galactosidase (Promega), $E(spl)$ proteins²⁹, Rough³⁰ and Delta²⁰.

Received 26 October; accepted 18 December 1998.

- Tomlinson, A. Cellular interactions in the developing eye. *Development* **104**, 183–193 (1988).
- Wolff, T. & Ready, D. F. in *The Development of Drosophila melanogaster* (eds Bate, M. & Martinez-Arias, A.) 1277–1325 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1993).
- Zheng, L., Zhang, J. & Carthew, R. W. *frizzled* regulates mirror-symmetric pattern formation in the *Drosophila* eye. *Development* **121**, 3045–3055 (1995).
- Fanto, M., Mayes, C. A. & Mlodzik, M. Linking cell-fate specification to planar polarity: determination of the R3/R4 photoreceptors is a prerequisite for the interpretation of the *Frizzled*. *Mech. Dev.* **74**, 51–58 (1998).
- Wolff, T. & Rubin, G. M. *strabismus*, a novel gene that regulates tissue polarity and cell fate decisions in *Drosophila*. *Development* **125**, 1149–1159 (1998).
- Theisen, H. et al. *dishevelled* is required during *wingless* signaling to establish both cell polarity and cell identity. *Development* **120**, 347–360 (1994).
- Krasnow, R. E., Wong, L. L. & Adler, P. N. *dishevelled* is a component of the *frizzled* signaling pathway in *Drosophila*. *Development* **121**, 4095–4102 (1995).
- Strutt, D. I., Weber, U. & Mlodzik, M. The role of RhoA in tissue polarity and *Frizzled* signalling. *Nature* **387**, 292–295 (1997).
- Boutros, M., Paricio, N., Strutt, D. I. & Mlodzik, M. *Dishevelled* activates JNK and discriminates between JNK pathways in planar polarity and *wingless* signaling. *Cell* **94**, 109–118 (1998).
- Wehrli, M. & Tomlinson, A. Independent regulation of anterior/posterior and equatorial/polar polarity in the *Drosophila* eye: evidence for the involvement of Wnt signaling in the equatorial/polar axis. *Development* **125**, 1421–1432 (1998).
- de Celis, J. F. et al. Functional relationships between *Notch*, *Su(H)* and the bHLH genes of the $E(spl)$ complex: the $E(spl)$ genes mediate only a subset of *Notch* activities during imaginal development. *Development* **122**, 2719–2728 (1996).

- Eastman, D. S. et al. Synergy between suppressor of Hairless and Notch in the regulation of *Enhancer of split* *my* and *mb* expression. *Mol. Cell. Biol.* **17**, 5620–5628 (1997).
- Cagan, R. L. & Ready, D. F. Notch is required for successive cell decisions in the developing *Drosophila* retina. *Genes Dev.* **3**, 1099–1112 (1989).
- Baker, N. E., Sung, Y. & Han, D. Evolution of proneural *atonal* expression during distinct regulatory phases in the developing *Drosophila* eye. *Curr. Biol.* **6**, 1290–1301 (1996).
- Struhl, G., Fitzgerald, K. & Greenwald, I. Intrinsic activity of the Lin-12 and Notch intracellular domains *in vivo*. *Cell* **74**, 331–345 (1993).
- Klein, T., Brennan, K. & Arias, A. M. An intrinsic dominant negative activity of serrate that is modulated during wing development in *Drosophila*. *Dev. Biol.* **189**, 123–134 (1997).
- Fortini, M. E., Rebay, L., Caron, L. A. & Artavanis-Tsakonas, S. An activated Notch receptor blocks cell-fate commitment in the developing *Drosophila* eye. *Nature* **365**, 555–557 (1993).
- Fischer-Vize, J. A., Vize, P. D. & Rubin, G. M. A unique mutation in the *Enhancer of split* gene complex affects the fates of the mystery cells in the developing *Drosophila* eye. *Development* **115**, 89–101 (1992).
- Axelrod, J. D., Matsuno, K., Artavanis-Tsakonas, S. & Perrimon, N. Interaction between *Wingless* and Notch signaling pathways mediated by *Dishevelled*. *Science* **271**, 1826–1832 (1996).
- Parks, A. L., Turner, F. R. & Muskavitch, M. A. T. Relationships between complex Delta expression and the specification of retinal cell fates during *Drosophila* eye development. *Mech. Dev.* **50**, 201–216 (1995).
- Greenwald, I. LIN-12/Notch signaling: lessons from worms and flies. *Genes Dev.* **12**, 1751–1762 (1998).
- Choi, K. W., Mozer, B. & Benzer, S. Independent determination of symmetry and polarity in the *Drosophila* eye. *Proc. Natl Acad. Sci. USA* **93**, 5737–5741 (1996).
- Gubb, D. Cellular polarity, mitotic synchrony and axes of symmetry during growth. Where does the information come from? *Int. J. Dev. Biol.* **42**, 369–377 (1998).
- Chen, C.-W. J., Jung, H.-S., Jiang, T.-X. & Chuong, C.-M. Asymmetric expression of Notch/Delta/Serrate is associated with the anterior-posterior axis of feather buds. *Dev. Biol.* **188**, 181–187 (1997).
- The, I. et al. Rescue of a *Drosophila* *NFI* mutant phenotype by Protein Kinase A. *Science* **276**, 791–794 (1997).
- Brand, A. H. & Perrimon, N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development* **118**, 401–415 (1993).
- Higashijima, S. et al. Dual *Bar* homeo box genes of *Drosophila* required in two photoreceptor cells, R1 and R6, and primary pigment cells for normal eye development. *Genes Dev.* **6**, 50–60 (1992).
- Fehon, R. G., Dawson, I. A. & Artavanis-Tsakonas, S. A *Drosophila* homolog of membrane skeleton protein-4.1 is associated with septate junctions and is encoded by the *coracle* gene. *Development* **120**, 545–547 (1994).
- Jennings, B., Preiss, A., Delidakis, C. & Bray, S. The Notch signalling pathway is required for *Enhancer of split* bHLH protein expression during neurogenesis in the *Drosophila* embryo. *Development* **120**, 3537–3548 (1994).
- Kimmel, B. E., Heberlein, U. & Rubin, G. M. The homeodomain protein Rough is expressed in a subset of cells in the developing *Drosophila* eye where it can specify photoreceptor subtype. *Genes Dev.* **4**, 712–727 (1990).

Acknowledgements. We thank R. Barrio, J. de Celis, M. Dominguez, D. Gubb and M. Haenlin for reagents; M. Dominguez for valuable advice; the multi-imaging center for technical assistance, and N. Brown, K. Moses and M. Freeman for comments on the manuscript. This research was supported by a Project Grant from the MRC and M.T.D.C. was funded by an MRC studentship.

Correspondence and requests for materials should be addressed to S.J.B. (sjb32@mole.bio.cam.ac.uk).

Cyclosporine induces cancer progression by a cell-autonomous mechanism

Minoru Hojo†, Takashi Morimoto‡, Mary Maluccio*, Tomohiko Asano§, Kengo Morimoto†, Milagros Lagman*, Toshikazu Shimbo† & Manikkam Suthanthiran*

* Department of Transplantation Medicine and Extracorporeal Therapy, Division of Nephrology, and Departments of Medicine and Surgery, Weill Medical College of Cornell University, 525 East 68th Street, New York, New York 10021, USA

† Department of Pediatrics, Mizonokuchi Hospital, Teikyo University School of Medicine, 3-8-3 Mizonokuchi, Takatsu-ku, Kawasaki 213, Japan

‡ Department of Cell Biology, New York University School of Medicine, 550 First Avenue, New York, New York 10016, USA

§ Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359, Japan

Malignancy is a common and dreaded complication following organ transplantation^{1–4}. The high incidence of neoplasm and its aggressive progression, which are associated with immunosuppressive therapy, are thought to be due to the resulting impairment of the organ recipient's immune-surveillance system^{5–9}. Here we report a mechanism for the heightened malignancy that is independent of host immunity. We show that cyclosporine (cyclosporin A), an immunosuppressant that has had a major impact on improving patient outcome following organ transplantation^{4,5}, induces phenotypic changes, including invasiveness of non-transformed cells, by a cell-autonomous mechanism.

Our studies show that cyclosporine treatment of adenocarcinoma cells results in striking morphological alterations, including membrane ruffling and numerous pseudopodial protrusions, increased cell motility, and anchorage-independent (invasive) growth. These changes are prevented by treatment with monoclonal antibodies directed at transforming growth factor- β (TGF- β). *In vivo*, cyclosporine enhances tumour growth in immunodeficient SCID-beige

mice; anti-TGF- β monoclonal antibodies but not control antibodies prevent the cyclosporine-induced increase in the number of metastases. Our findings suggest that immunosuppressants like cyclosporine can promote cancer progression by a direct cellular effect that is independent of its effect on the host's immune cells, and that cyclosporine-induced TGF- β production is involved in this.

We explored an alternative and autonomous cellular mechanism





Figure 1 Cyclosporine induces A-549 cells to acquire an invasive phenotype. Scanning electron microscopic photographs of A-549 cells grown on glass coverslips and incubated for 72 h with: nothing (control cells, **a**, **b**); 1 μ g ml⁻¹ cyclosporine (**c**, **d**); 2 ng ml⁻¹ recombinant TGF- β ₁ protein (**e**, **f**); 1 μ g ml⁻¹ cyclosporine plus 30 μ g ml⁻¹ anti-TGF- β (**g**, **h**). Note that cyclosporine-conditioned cells, in a similar fashion to TGF- β -treated cells, display membrane ruffling and acquire exploratory pseudopodia, and that anti-TGF- β antibodies prevent these cyclosporine-induced morphological alterations. Scale bars, 10 μ m. **i**, TGF- β concentrations (mean \pm s.d.) in supernatants obtained from untreated or cyclosporine-treated A-549 cells. The cells were incubated for 72 h, in the absence or presence of 0.5 or 1.0 μ g ml⁻¹ cyclosporine, and a sandwich ELISA assay¹¹ was used to quantify TGF- β levels.





Figure 2 Cyclosporine stimulates the motility of A-549 cells. A-549 cells were grown for 72 h on 10-mm round polycarbonate membrane filters with 0.4 μ m (**a**, **b**) or 3 μ m (**c**, **d**) pore size in the absence (**a**, **c**) or presence (**b**, **d**) of 1 μ g ml⁻¹ cyclosporine. The filters were removed from the culture dishes and the bottom surfaces were examined by scanning electron microscopy. Note that the pseudopodia of cyclosporine-treated cells grown on 0.4- μ m pore size filters protrude through the pores to the bottom surface (**b**) whereas cyclosporine-treated cells grown on 3- μ m pore filters migrate through the pores onto the bottom surface (**d**). Scale bars, 10 μ m. **e**, Cyclosporine promotes migration of A-549 cells. A-549 cells were placed in the upper chamber of 12-well transwells (8 μ m pore) at a density of 10^5 cells, and were incubated alone or with 0.5 or 1.0 μ g ml⁻¹ cyclosporine or with 1.0 μ g ml⁻¹ cyclosporine plus 30 μ g ml⁻¹ anti-TGF- β antibodies (Ab). The cells that migrated into the lower chamber through the 8- μ m pores of the polycarbonate membrane filters were counted after the cells had been dissociated by trypsinization. Results (mean \pm s.e.m.) are of three experiments carried out with duplicate samples.

for immunosuppressant-associated tumour progression. We tested the hypothesis that cyclosporine, independently of any effects on the host immune system, would programme non-invasive cells to acquire an invasive phenotype. The experimental basis for our hypothesis was our demonstration that cyclosporine promotes the transcription and functional expression of the TGF- β_1 gene^{10,11} and the observation by others that TGF- β can promote tumour-cell invasion and metastasis¹²⁻¹⁴.

A non-transformed human pulmonary adenocarcinoma (A-549) cell line¹⁴ that is not invasive *in vitro* was used as the indicator cell to test the hypothesis that cyclosporine can induce an invasive phenotype. A-549 cells express functional receptors for TGF- β , and their growth and function are regulated by TGF- β (refs 11, 14). We carried out these experiments *ex vivo* to avoid any confounding effects of cyclosporine-associated inhibition of *in vivo* immune surveillance mechanisms.

Figure 1 shows the striking morphological changes observed following cyclosporine treatment of A-549 cells. Scanning electron microscopic examination revealed that untreated A-549 cells display a cuboidal epithelial and non-invasive phenotype (Fig. 1a, b), whereas cyclosporine-treated cells show phenotypic alterations that are characteristic of invasive cells, that is, marked membrane ruffling and the formation of numerous pseudopodia (Fig. 1c, d). Additional data (Fig. 1) support the hypothesis that the cyclosporine-induced acquisition of an invasive phenotype is due

to TGF- β . First, cyclosporine stimulated TGF- β secretion by A-549 cells in a concentration-dependent manner (Fig. 1i); second, anti-TGF- β monoclonal antibodies (1D11.16 IgG)₁¹⁵, in contrast to control IgG₁ monoclonal antibodies, prevented the cyclosporine-induced morphological alterations (Fig. 1g, h); and third, recombinant TGF- β_1 induced morphological alterations in A-549 cells that were similar to those elicited by cyclosporine (Fig. 1e, f). Our finding that cyclosporine stimulates TGF- β_1 production in A-549 cells extends earlier observations that it induces T cells¹⁰, CCL-64 mink lung epithelial cells¹¹ and renal cells¹⁶ to hyperexpress TGF- β_1 . The phenotypic changes elicited by cyclosporine were reversible; incubation of cyclosporine-treated A-549 cells in cyclosporine-free culture medium for 48 h resulted in the reversal of the invasive phenotype and a return to the original morphology (data not shown).

Cells capable of locomotion and invasiveness display exploratory pseudopodia^{17,18}. Because cyclosporine induced numerous, long pseudopodia in A-549 cells, we investigated whether such cells acquired motility. To explore this, A-549 cells were seeded on polycarbonate membrane filters with three pore sizes (0.4, 3 and 8 μ m) in the presence or absence of cyclosporine; and the bottom surfaces of the membrane filters were examined by scanning electron microscopy. Our results show that many cyclosporine-induced pseudopodia protrude through 0.4- μ m pores onto the bottom surface (Fig. 2b), whereas only a few pseudopodia protrude in the control (Fig. 2a). When the cells were grown on 3- μ m pore filters, many cyclosporine-treated cells and only few untreated cells, migrated through the pores to the bottom surface of the membrane filter (Fig. 2c, d).

To quantify the cell motility resulting from cyclosporine treatment, we used 8- μ m pore filters in the migration assay. We found that the number of A-549 cells that migrated increased in proportion to the concentration of cyclosporine used to treat the cells, and that the increased cell motility was suppressed by anti-TGF- β antibodies (Fig. 2e), but not by the control IgG₁ antibodies. Thus, cyclosporine-induced alterations in both morphology (Fig. 1) and cell motility (Fig. 2) were dependent on cyclosporine-induced TGF- β production.

Anchorage-independent growth *in vitro* is considered a correlate of invasive tumour growth *in vivo*^{19,20}, and so we next examined whether cyclosporine treatment results in anchorage-independent growth. A-549 cells were plated on soft agarose gels and grown for 96 h (Fig. 3, see legend for details). Phase-contrast microscopic examination revealed that untreated A-549 cells retained their spherical shape and remained suspended in the culture medium, whereas cyclosporine-treated cells spread and proliferated strongly on the soft gel (Fig. 3a, b). Because it was difficult to determine by phase-contrast microscopy whether the pseudopodia extended along the surface of the agarose or penetrated deeper into the agarose layer, we made vertical thin sections of the soft gels and examined them by scanning electron microscopy to obtain side views. This strategy revealed that many fully grown pseudopodia of the cyclosporine-treated cells penetrated the agarose-gel layer and extended vertically into the gel plate (Fig. 3d). Also, these cells appeared to be supported by the extensively invaded pseudopodia, in contrast to the absence of pseudopodial extensions in the control A-549 cells (Fig. 3c).

Cyclosporine's effect on A-549 cells growth was contingent upon whether the culture conditions were anchorage-dependent or -independent. It inhibited the proliferation of A-549 cells under anchorage-dependent conditions but stimulated proliferation under anchorage-independent conditions (Fig. 3e, f).

We next examined whether cyclosporine induces morphological and functional alterations in other cell types, looking at murine renal cell adenocarcinoma (Renca) cells, mouse mammary gland epithelial (NMuMG) cells and mink lung epithelial (CCL-64) cells. We found that cyclosporine treatment produced phenotypic




Figure 3 Anchorage-independent growth of cyclosporine-conditioned A-549 cells. Culture medium (3 ml) containing 10^4 cells and $1 \mu\text{g ml}^{-1}$ cyclosporine (b, d) or no cyclosporine (a, c) was loaded onto 5 ml of a 0.3% agarose layer containing MEM-10% FBS in 60-mm dishes. After 96 h incubation at 37°C , cells grown on the surface of the agarose layer were examined with a phase-contrast microscope (a, b). For scanning electron microscopic observation (c, d), the soft gels were fixed and then vertical thin sections were made. These slices were processed for scanning electron microscopy as described in Methods. Twenty slices were made from each agarose plate, and representative ones are shown. Note that pseudopodia of cyclosporine-treated A-549 cells protrude deeply into the soft gel under anchorage-independent growth conditions. Scale bars, $10 \mu\text{m}$. e, Cyclosporine-associated inhibition of anchorage-dependent proliferation of A-549 cells; f, cyclosporine-induced stimulation of anchorage-independent growth.

alterations in these epithelial cells as well. A representative example (Fig. 4a, b) shows that cyclosporine-treated Renca cells, in a similar fashion to cyclosporine-treated A-549 cells, display an invasive phenotype.

We investigated whether cyclosporine would enhance the invasive and metastatic growth of tumour cells *in vivo* using Renca cells²¹, and two other tumour cell lines, mouse-derived Lewis lung carcinoma cells²² and human bladder transitional carcinoma cells²³, as the tumour inoculum. SCID-beige mice (mice homozygous for both *SCID* and *beige* mutations²⁴), which are deficient in T cells, B cells and natural killer cells, were used as the host. The use of SCID-beige mice minimized the possibility that cyclosporine-induced depression of the host's immune system contributed to tumour progression.

Cyclosporine increased the number of murine renal carcinoma metastases in SCID-beige mice (Fig. 4c, d). Data from four separate experiments showed that the number of renal cell cancer pulmonary metastases was 241 ± 22 (mean \pm s.e.m., $n = 21$) in the control SCID-beige mice compared with 338 ± 26 ($n = 18$) in the cyclosporine-treated mice ($P = 0.007$; *t*-test) (Table 1). Also, the number of pulmonary metastases resulting from inoculation of murine Lewis lung carcinoma cells was 11 ± 2 ($n = 9$ mice) in the control mice compared with 28 ± 4 ($n = 8$ mice) with cyclosporine treatment ($P = 0.003$), while the number of pulmonary metastases resulting from inoculation of human bladder transitional cancer cells was 63 ± 18 ($n = 9$ mice) in controls and 138 ± 21 ($n = 9$ mice) in cyclosporine-treated mice ($P = 0.01$) (Table 1).

We investigated the effect of anti-TGF- β antibodies (1D11.16 IgG₁)¹⁵ on the cyclosporine-induced increase in the metastases to determine whether *in vivo* tumour progression by cyclosporine was dependent on TGF- β . Anti-TGF- β antibodies, but not control IgG₁ antibodies, prevented the cyclosporine-induced increase in metastases. The number of pulmonary metastases was 350 ± 22 (mean \pm s.e.m., $n = 12$) in the control mice, 441 ± 20 ($n = 10$) in cyclosporine-treated mice, 284 ± 34 ($n = 8$) in mice treated with both cyclosporine and anti-TGF- β , and 490 ± 56 ($n = 4$) in mice treated with cyclosporine and control IgG₁ ($P = 0.0005$; one-way ANOVA). The reduction in the number

Table 1 Cyclosporine increases pulmonary metastases in SCID-beige mice

Tumour inoculum	Number of pulmonary metastases (mean \pm s.e.m.)		
	Without CsA	With CsA	<i>P</i> *
Murine Renca	241 ± 22 ($n = 21$)	338 ± 26 ($n = 18$)	0.007
Murine Lewis lung carcinoma (LLC)	11 ± 2 ($n = 9$)	28 ± 4 ($n = 8$)	0.003
Human bladder cancer (T24)	63 ± 18 ($n = 9$)	138 ± 21 ($n = 9$)	0.01

Tumour cells (1×10^5 or 5×10^5 in HBSS) were injected in the tail vein of SCID-beige mice. Cyclosporine (cyclosporin A; CsA; 20 mg per kg) was administered every other day from day -1 to the day of death. The mice were killed on day 19 (Renca), 16 (LLC) or 23 (T24), and the number of metastases was counted as described²⁰. *n*, Number of mice in each group; *P* value derived with *t*-test.

of metastases found following the administration of anti-TGF- β antibodies to cyclosporine-treated mice was significant at $P < 0.01$ by ANOVA (Bonferroni *P*-value). In contrast, there was no significant difference between the number of metastases found in cyclosporine-treated mice and that found in mice treated with combined cyclosporine and control IgG₁ ($P > 0.05$). Our *in vitro* experiments show that the tumour cells are the sole source of TGF- β (Figs 1, 2). Many cell types, in addition to tumour cells, might contribute to cyclosporine-induced TGF- β hyperexpression *in vivo*.

The malignancy-promoting effects of immunosuppressive drugs are thought to result from drug-induced T-lymphocyte dysfunction and resultant immunosuppression. On the other hand, the production of TGF- β by tumours represents a potential mechanism by which they evade the host's immune system²⁵⁻²⁸. Our demonstration that cyclosporine-treated, non-transformed cells acquire invasiveness under *in vitro* conditions that allow no possible involvement of the host's immune system, and our *in vivo* data that cyclosporine promotes tumour growth in SCID-beige mice, suggest a cell-autonomous mechanism for cancer progression (Fig. 5). Specific therapeutic strategies that target pathways responsible for heightened invasiveness (such as TGF- β regulation) are worth exploring and may be of value to people who are given allografts and to other individuals at increased risk of neoplasms. □




Figure 4 Cyclosporine induces renal cancer cells to acquire an invasive phenotype and promotes tumour growth *in vivo*. Scanning electron micrograph of murine renal adenocarcinoma cells incubated for 72 h in the absence (a) or presence of $1 \mu\text{g ml}^{-1}$ cyclosporine (b). Scale bars, $10 \mu\text{m}$. Representative lungs, retrieved from untreated mice (c) and from cyclosporine-treated mice (d), are shown to illustrate the cyclosporine-associated increase in renal cell cancer pulmonary metastasis in SCID-beige mice.




Figure 5 Potential mechanisms for cyclosporine-associated tumour progression. In this formulation, cyclosporine induced TGF- β production by tumour cells promotes cell invasiveness by a cell-autonomous mechanism that is independent of and/or complementary to cyclosporine's immunosuppressive effect on the host's immune system.

Methods

Cell line and culture. Human lung adenocarcinoma cells (A-549 cells; ATCC CCL 185; American Type Culture Collection, Rockville, MD), human bladder transitional carcinoma cells (ATCC HTB4, T24), mink lung epithelial cells (CCL-64; ATCC), mouse mammary gland epithelial cells (NMuMG; ATCC) and Lewis lung carcinoma cells (ATCC) were grown in minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), at 37 °C in a 95% air–5% CO₂ atmosphere. Murine renal adenocarcinoma cells (Renca cells; a gift from R. H. Wiltout, National Cancer Institute) were maintained by *in vivo* serial passages in syngeneic BALB/c mice, as described²¹.

Scanning electron microscopy. Cells were seeded at a density of 10⁵ on 12-mm round glass coverslips or 10-mm round polycarbonate membrane filters (0.4 or 3 µm pore size) in 12-well Transwells (Costar), and grown for 72 h in the presence or absence of cyclosporine. To assess the ability of TGF-β-specific antibody to inhibit cyclosporine-mediated effects, A-549 cells were incubated in the presence of both cyclosporine and monoclonal antibodies (Genzyme) that recognize TGF-β₁, -β₂ and -β₃. Cells were fixed with PBS, pH 7.4, containing 2.0% glutaraldehyde, and processed as previously described²⁹. Samples were examined using a JEOL 255III electron microscope.

Quantification of TGF-β. TGF-β was quantified using a sandwich enzyme-linked immunosorbent assay (ELISA) method as previously described¹¹. In brief, each well of multiwell ELISA assay plates was coated with anti-TGF-β₁ antibodies (1 µg ml⁻¹). The plates were incubated for 2 h at 37 °C after the addition of various amounts of TGF-β₁ in PBS or conditioned medium. After washing with PBS containing 0.2% Tween-20 (PBST), rabbit antiserum against TGF-β was added to each well. The plates were incubated at 37 °C for 1 h, the wells were washed with PBST, and then 100 µl of goat anti-rabbit IgG–alkaline phosphatase conjugates was added. Absorbance at 430 nm was measured using an ELISA assay reader. A-549 cells were cultured in serum-free medium to exclude contamination of cell-free supernatants by serum-derived TGF-β.

Cell proliferation assay. For assaying anchorage-dependent growth, A-549 cells were grown at a density of 2 × 10⁴ cells per well in 12-well plates in the presence or absence of cyclosporine. After 96 h treatment, each well received 2 µCi of methyl-³H-thymidine, and cells were incubated for an additional 4 h. They were washed twice with ice-cold PBS and fixed with methanol for 60 min. After washing, the fixed cells were lysed with 0.2 M NaOH and treated with cold 10% trichloroacetic acid (TCA) for 15–20 min on ice. The radioactivity, recovered as cold TCA-insoluble precipitates, was used for measuring relative cell proliferation by comparing the radioactivity between control and experiment. For an anchorage-independent cell growth, cells spread well on agarose gel were counted using a phase-contrast microscope.

***In vivo* tumour growth.** Murine renal cell adenocarcinoma cells (1 × 10⁵ in Hank's balanced salt solution; HBSS), murine Lewis lung carcinoma cells (5 × 10⁵ cells) or human bladder cancer cells (1 × 10⁵ cells) were injected in the tail vein of 6-week-old male SCID–beige mice. Cyclosporine (20 mg per kg in 0.2 ml olive oil) was administered every other day starting from day –1, to day 19 or 23 after tumour inoculation. On day 19 or 23 after tumour inoculation, mice were killed and the number of pulmonary metastases was determined³⁰ following endotracheal insufflation of lungs with 15% India ink solution and bleaching the collected lungs in Fekete's solution. The effect of anti-TGF-β antibody and the control IgG₁ antibody on the cyclosporine-induced increase in the number of pulmonary metastases was determined by intraperitoneal administration of 200 µg of antibody, on a daily basis starting from day –1 to day 19 after tumour inoculation.

Received 21 September; accepted 15 December 1998.

- Penn, I. Cancers following cyclosporine therapy. *Transplantation* **43**, 32–35 (1987).
- Yokoyama, I., Carr, B., Saito, H., Iwatsuki, S. & Starzl, T. E. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. *Cancer* **68**, 2095–2100 (1991).
- London, N. J., Farmery, S. M., Will, E. J., Davison, A. M. & Lodge, J. P. A. Risk of neoplasia in renal transplant patients. *Lancet* **346**, 403–406 (1995).
- Suthanthiran, M. & Strom, T. B. Renal transplantation. *N. Engl. J. Med.* **331**, 365–376 (1994).
- Kahan, B. D. Cyclosporine. *N. Engl. J. Med.* **321**, 1725–1738 (1989).
- Shimizu, T., Martin, M. S., Pelletier, H., Lagadee, P. & Martin, F. Effects of cyclosporin A on progressive and regressive tumors induced by two cancer lines derived from a single colon carcinoma chemically induced in the rat. *Immunobiology* **178**, 401–415 (1989).
- Van de Vrie, W., Marquet, R. L. & Eggermont, A. M. M. Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumor. *J. Cancer Res. Clin. Oncol.* **123**, 21–24 (1997).
- Van der Elst, J. et al. Quantitative study of liver metastasis from colon cancer in rats after treatment with Cyclosporine A. *J. Natl Cancer Inst.* **77**, 227–232 (1986).
- Masuhara, M., Ogasawara, H., Katyal, S. L., Nakamura, T. & Shinozuka, H. Cyclosporine stimulates

hepatocyte proliferation and accelerates development of hepatocellular carcinomas in rats. *Carcinogenesis* **14**, 1579–1584 (1993).

- Li, B. et al. Differential regulation of transforming growth factor-β and interleukin 2 genes in human T cells: Demonstration by usage of novel competitor DNA constructs in quantitative polymerase chain reaction. *J. Exp. Med.* **174**, 1259–1262 (1991).
- Khanna, A., Li, B., Stenzel, K. H. & Suthanthiran, M. Regulation of new DNA synthesis in mammalian cells by cyclosporine. *Transplantation* **57**, 577–582 (1994).
- Welch, D. R., Fabra, A. & Nakajima, M. Transforming growth factor-β stimulates mammary adenocarcinoma cell invasion and metastatic potential. *Proc. Natl Acad. Sci. USA* **87**, 7678–7682 (1990).
- Caulin, C., Scholl, F. G., Frontelo, P., Gamallo, C. & Quntanilla, M. Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-β₁ induces an epithelial–mesenchymal transdifferentiation and a spindle tumoral phenotype. *Cell Growth Differ.* **6**, 1027–1035 (1995).
- Mooradian, D. L., McCarthy, J. B., Komanduri, K. V. & Furcht, L. T. Effects of transforming growth factor-β₁ on human pulmonary adenocarcinoma cell adhesion, motility, and invasion *in vitro*. *J. Natl Cancer Inst.* **84**, 523–527 (1992).
- Dasch, J. R., Pace, D. R., Waigell, W., Inenaga, D. & Ellingsworth, L. Monoclonal antibodies recognizing transforming growth factor-β. Bioactivity neutralization and transforming growth factor-β₂ affinity purification. *J. Immunol.* **142**, 1536–1541 (1989).
- Wolf, G., Thaisz, F. & Stahl, R. A. Cyclosporine stimulates expression of transforming growth factor-β in renal cells: Possible mechanism of cyclosporine's anti-proliferative effects. *Transplantation* **60**, 237–241 (1995).
- Guirguis, R., Margulies, I., Tarabotti, G., Schiffmann, E. & Liotta, L. Cytokine-induced pseudopodial protrusion is coupled to tumor cell migration. *Nature* **329**, 261–263 (1987).
- Couchman, J. R., Lenn, M. & Rees, D. A. Coupling of cytoskeletal functions for fibroblast locomotion. *Eur. J. Cell Biol.* **36**, 182–194 (1985).
- Freeman, V. H. & Shin, S. Cellular tumorigenicity in nude mice: Correlation with cell growth in semi-solid medium. *Cell* **3**, 355–359 (1974).
- Massagué, J. Transforming growth factor-β family. *Annu. Rev. Cell Biol.* **6**, 597–641 (1990).
- Murphy, G. P. & Hruschsky, W. J. A murine renal cell carcinoma. *J. Natl Cancer Inst.* **50**, 1013–1025 (1973).
- Bertram, J. S. & Janik, P. Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture. *Cancer Lett.* **11**, 63–73 (1980).
- Bubenik, J. et al. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. *Int. J. Cancer* **11**, 765–773 (1973).
- Mosier, D. E., Stell, K. L., Gulizia, R. J., Torbett, B. E. & Gilmore, G. L. Homozygous scid/scid; beige/beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation. *J. Exp. Med.* **177**, 191–194 (1993).
- Cui, W. et al. TGF-β₁ inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. *Cell* **86**, 531–542 (1996).
- Arega, C. I. et al. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. *J. Clin. Invest.* **92**, 2569–2576 (1993).
- Torre-Aminoe, G. et al. A highly immunogenic tumor transfected with a murine transforming growth factor-β₁ cDNA escapes immune surveillance. *Proc. Natl Acad. Sci. USA* **87**, 1486–1490 (1990).
- Arrick, B. A. et al. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor-β₁. *J. Cell Biol.* **118**, 715–726 (1992).
- Cohen-Gould, L., Robinson, T. F. & Factor, S. M. Intrinsic connective tissue abnormalities in the heart muscle of cardiomyopathy Syrian hamsters. *Am. J. Pathol.* **127**, 327–334 (1987).
- Asano, T., Khanna, A., Lagman, M., Li, B. & Suthanthiran, M. Immunostimulatory therapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2: Heightened *in vivo* expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of murine renal cell carcinoma. *J. Urol.* **157**, 2396–2401 (1997).

Acknowledgements. We thank Y. Suzuki for technical assistance, B. Li, R. Ding, A. Khanna, V. K. Sharma and A. Niwa for their help; P. August, M. Ono and Y. Ichihashi for critical review of the manuscript; B. Pratt, D. Pappas and D. Felson for the generous gift and advice regarding 1D11.16 antibodies direct at TGF-β₁ and L. Stackhouse for help in the preparation of this manuscript. This work was supported in part by a grant from the Ministry of Education, Science and Culture, Japan (M.H.), Kanagawa Academy of Science and Technology, Japan (M.H.), and by an award from the National Institutes of Health, USA (M.S.).

Correspondence and requests for materials should be addressed to M.H.

RGD peptides induce apoptosis by direct caspase-3 activation

Christopher D. Buckley[†], Darrell Pilling[†], Nick V. Henriquez[†], Greg Parsonage^{*}, Katy Threlfall^{*}, Dagmar Scheel-Toellner^{*}, David L. Simmons[§], Arne N. Akbar[§], Janet M. Lord^{*} & Mike Salmon^{*}

^{*} Division of Immunity and Infection, and [†] Institute for Cancer Studies, MRC Centre for Immune Regulation, The University of Birmingham, Birmingham B15 2TT, UK

[§] Department of Neuroscience, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK

[§] Department of Clinical Immunology, Royal Free and University College Medical School, Pond Street, London NW3 2PF, UK

[†] These authors contributed equally to this work

Synthetic peptides containing the arginine–glycine–aspartate (RGD) motif have been used extensively as inhibitors of integrin–ligand interactions in studies of cell adhesion, migration, growth and differentiation^{1–3}, because the RGD motif is an integrin-recognition motif found in many ligands. Here we report